Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Predictive Genetic Testing Consumer Wellness Genomics Market

ID: MRFR/LS/50118-HCR
200 Pages
Satyendra Maurya
Last Updated: March 28, 2026

UK Predictive Genetic Testing and Consumer Wellness Genomics Market Research Report By Test Type (Predictive Testing, Consumer Genomics, Wellness Genomics), By Application (Breast & Ovarian Cancer, Cardiovascular Screening, Diabetic Screening & Monitoring, Colon Cancer, Parkinsonism/Alzheimer’s Disease, Urologic Screening/Prostate Cancer Screening, Orthopedic & Musculoskeletal, Others), and By Setting Type (Proteomic Testing, Metabolic Testing, Genomic Testing) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Predictive Genetic Testing Consumer Wellness Genomics Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Million)
  49.     4.1.1 Disease Risk Assessment
  50.     4.1.2 Carrier Testing
  51.     4.1.3 Pharmacogenomics
  52.     4.1.4 Nutrigenomics
  53.     4.1.5 Ancestry Testing
  54.   4.2 Healthcare, BY End Use (USD Million)
  55.     4.2.1 Healthcare Providers
  56.     4.2.2 Research Institutions
  57.     4.2.3 Direct-to-Consumer
  58.     4.2.4 Pharmaceutical Companies
  59.     4.2.5 Insurance Companies
  60.   4.3 Healthcare, BY Technology (USD Million)
  61.     4.3.1 Next Generation Sequencing
  62.     4.3.2 Polymerase Chain Reaction
  63.     4.3.3 Microarray Technology
  64.     4.3.4 Sanger Sequencing
  65.     4.3.5 Digital PCR
  66.   4.4 Healthcare, BY Test Type (USD Million)
  67.     4.4.1 Single Gene Testing
  68.     4.4.2 Panel Testing
  69.     4.4.3 Whole Exome Sequencing
  70.     4.4.4 Whole Genome Sequencing
  71.     4.4.5 Targeted Gene Panels
  72.   4.5 Healthcare, BY Consumer Segment (USD Million)
  73.     4.5.1 Health Conscious Individuals
  74.     4.5.2 Families Planning for Children
  75.     4.5.3 Individuals with Family History of Genetic Disorders
  76.     4.5.4 Fitness Enthusiasts
  77.     4.5.5 Aging Population
  78. 5 SECTION V: COMPETITIVE ANALYSIS
  79.   5.1 Competitive Landscape
  80.     5.1.1 Overview
  81.     5.1.2 Competitive Analysis
  82.     5.1.3 Market share Analysis
  83.     5.1.4 Major Growth Strategy in the Healthcare
  84.     5.1.5 Competitive Benchmarking
  85.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  86.     5.1.7 Key developments and growth strategies
  87.       5.1.7.1 New Product Launch/Service Deployment
  88.       5.1.7.2 Merger & Acquisitions
  89.       5.1.7.3 Joint Ventures
  90.     5.1.8 Major Players Financial Matrix
  91.       5.1.8.1 Sales and Operating Income
  92.       5.1.8.2 Major Players R&D Expenditure. 2023
  93.   5.2 Company Profiles
  94.     5.2.1 23andMe (GB)
  95.       5.2.1.1 Financial Overview
  96.       5.2.1.2 Products Offered
  97.       5.2.1.3 Key Developments
  98.       5.2.1.4 SWOT Analysis
  99.       5.2.1.5 Key Strategies
  100.     5.2.2 Genomics England (GB)
  101.       5.2.2.1 Financial Overview
  102.       5.2.2.2 Products Offered
  103.       5.2.2.3 Key Developments
  104.       5.2.2.4 SWOT Analysis
  105.       5.2.2.5 Key Strategies
  106.     5.2.3 MyHeritage (GB)
  107.       5.2.3.1 Financial Overview
  108.       5.2.3.2 Products Offered
  109.       5.2.3.3 Key Developments
  110.       5.2.3.4 SWOT Analysis
  111.       5.2.3.5 Key Strategies
  112.     5.2.4 Ancestry (GB)
  113.       5.2.4.1 Financial Overview
  114.       5.2.4.2 Products Offered
  115.       5.2.4.3 Key Developments
  116.       5.2.4.4 SWOT Analysis
  117.       5.2.4.5 Key Strategies
  118.     5.2.5 Fulgent Genetics (GB)
  119.       5.2.5.1 Financial Overview
  120.       5.2.5.2 Products Offered
  121.       5.2.5.3 Key Developments
  122.       5.2.5.4 SWOT Analysis
  123.       5.2.5.5 Key Strategies
  124.     5.2.6 Illumina (GB)
  125.       5.2.6.1 Financial Overview
  126.       5.2.6.2 Products Offered
  127.       5.2.6.3 Key Developments
  128.       5.2.6.4 SWOT Analysis
  129.       5.2.6.5 Key Strategies
  130.     5.2.7 Invitae (GB)
  131.       5.2.7.1 Financial Overview
  132.       5.2.7.2 Products Offered
  133.       5.2.7.3 Key Developments
  134.       5.2.7.4 SWOT Analysis
  135.       5.2.7.5 Key Strategies
  136.     5.2.8 Color Genomics (GB)
  137.       5.2.8.1 Financial Overview
  138.       5.2.8.2 Products Offered
  139.       5.2.8.3 Key Developments
  140.       5.2.8.4 SWOT Analysis
  141.       5.2.8.5 Key Strategies
  142.     5.2.9 Gene by Gene (GB)
  143.       5.2.9.1 Financial Overview
  144.       5.2.9.2 Products Offered
  145.       5.2.9.3 Key Developments
  146.       5.2.9.4 SWOT Analysis
  147.       5.2.9.5 Key Strategies
  148.   5.3 Appendix
  149.     5.3.1 References
  150.     5.3.2 Related Reports
  151. 6 LIST OF FIGURES
  152.   6.1 MARKET SYNOPSIS
  153.   6.2 UK MARKET ANALYSIS BY APPLICATION
  154.   6.3 UK MARKET ANALYSIS BY END USE
  155.   6.4 UK MARKET ANALYSIS BY TECHNOLOGY
  156.   6.5 UK MARKET ANALYSIS BY TEST TYPE
  157.   6.6 UK MARKET ANALYSIS BY CONSUMER SEGMENT
  158.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  159.   6.8 RESEARCH PROCESS OF MRFR
  160.   6.9 DRO ANALYSIS OF HEALTHCARE
  161.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  162.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  163.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  164.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  165.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
  166.   6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
  167.   6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
  168.   6.17 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
  169.   6.18 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
  170.   6.19 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
  171.   6.20 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Million)
  172.   6.21 HEALTHCARE, BY CONSUMER SEGMENT, 2024 (% SHARE)
  173.   6.22 HEALTHCARE, BY CONSUMER SEGMENT, 2024 TO 2035 (USD Million)
  174.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  175. 7 LIST OF TABLES
  176.   7.1 LIST OF ASSUMPTIONS
  177.     7.1.1
  178.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  179.     7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  180.     7.2.2 BY END USE, 2026-2035 (USD Million)
  181.     7.2.3 BY TECHNOLOGY, 2026-2035 (USD Million)
  182.     7.2.4 BY TEST TYPE, 2026-2035 (USD Million)
  183.     7.2.5 BY CONSUMER SEGMENT, 2026-2035 (USD Million)
  184.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  185.     7.3.1
  186.   7.4 ACQUISITION/PARTNERSHIP
  187.     7.4.1

UK Healthcare Market Segmentation

Healthcare By Application (USD Million, 2026-2035)

  • Disease Risk Assessment
  • Carrier Testing
  • Pharmacogenomics
  • Nutrigenomics
  • Ancestry Testing

Healthcare By End Use (USD Million, 2026-2035)

  • Healthcare Providers
  • Research Institutions
  • Direct-to-Consumer
  • Pharmaceutical Companies
  • Insurance Companies

Healthcare By Technology (USD Million, 2026-2035)

  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Microarray Technology
  • Sanger Sequencing
  • Digital PCR

Healthcare By Test Type (USD Million, 2026-2035)

  • Single Gene Testing
  • Panel Testing
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • Targeted Gene Panels

Healthcare By Consumer Segment (USD Million, 2026-2035)

  • Health Conscious Individuals
  • Families Planning for Children
  • Individuals with Family History of Genetic Disorders
  • Fitness Enthusiasts
  • Aging Population

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓